JAMA Network Home
Sign In
Research Letter

Variation in US Commercial Health Plan Coverage Restrictions for Cell and Gene Therapies

JAMA 10.1001/jama.2025.15148

September 29, 2025 at 11:00 AM EDT

Read the full article

This Viewpoint examines variations in US commercial health plan coverage restrictions for cell and gene therapies.

Corresponding Author: James D. Chambers, PhD, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, 800 Washington St, #63, Boston, MA 02111 (james.chambers@tuftsmedicine.org).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.15148?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=092925

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks